The Parisian biotech company specializing in inflammatory diseases is recovering ground mid-morning, following several weeks ...

The Paris-based biotech company specializing in nanomedicine for oncology extends its downward slide at midday, in an SBF 120 ...

Susan Bobulsky is identified as an officer of Adaptive Biotechnologies Corporation. Shares proposed for sale: 6,444 common ...

EQS-News: AXIM Biotech / Key word (s): Financial AXIM Biotechnologies Submits 510 (k) to FDA for Next-Generation, Rapid Point-of-Care Tear Lactoferrin Test for Dry Eye Disease 06.10.2026 / 15:00 ...

Adaptive Biotechnologies Corp’s stock reached a 52-week high, hitting $30.10, marking a significant milestone for the company ...

Learn more about whether Adaptive Biotechnologies Corporation or Fortrea Holdings Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Fintel reports that on 29 September 2026, Goldman Sachs initiated coverage of Adaptive Biotechnologies (MUN:1HM) with a Buy recommendation. Adaptive Biotechnologies Corporation, based in the United ...

The average one-year price target for Adaptive Biotechnologies (NASDAQGS:ADPT) (MUN:1HM) has been revised to $28.05 / share. This is an increase of 11.11% from the prior estimate of $25.24 dated ...

View Adaptive Biotechnologies Corp. ADPT stock quote prices, financial information, real-time forecasts, and company news from CNN.

Guggenheimanalyst Subbu Nambi maintains $Adaptive Biotechnologies(ADPT.US)$ with a buy rating, and adjusts the target price ...

Adaptive Biotechnologies Corporation (ADPT) is down 3.5% today. Here is some analysis on what might have caused this price movement. Analysis: The catalyst is not fully clear, but the move appears ...

Bio-Rad Laboratories tumbled 5.2% on Thursday as a sector-wide selloff dragged down medical device and life sciences stocks ...